US Broker Ratings

Cel-Sci Corporation (CVM) Investor Outlook: Unveiling a 498% Potential Upside in Biotechnology

For investors seeking high-stakes opportunities in the biotechnology sector, Cel-Sci Corporation (NASDAQ: CVM) presents a compelling case with a potential upside of nearly 498.09%. This clinical-stage..

Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotechnology Innovator Poised for 130% Upside

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company specializing in precision medicines for kidney and metabolic diseases, stands out in the healthcare sector with a..

Myriad Genetics, Inc. (MYGN) Stock Analysis: Navigating the Diagnostic Frontier with a Cautionary Outlook

For investors eyeing the healthcare sector, Myriad Genetics, Inc. (NASDAQ: MYGN) presents an intriguing, albeit challenging, proposition. A cornerstone in the diagnostics and research industry, Myriad..

AngioDynamics, Inc. (ANGO)

⚠️ No article content returned.

..

Rapport Therapeutics (RAPP) Stock Analysis: Exploring a Promising 91% Upside in the Biotech Sector

Rapport Therapeutics, Inc. (NASDAQ: RAPP), a rising player in the biotechnology industry, is gaining traction with investors due to its ambitious focus on developing transformative treatments..

AtaiBeckley Inc. (ATAI): Investor Outlook on a Biotech Innovator with a Promising 10% Upside

AtaiBeckley Inc. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company with a focus on mental health treatments, is capturing attention in the healthcare sector. Based in New York,..

Autolus Therapeutics plc (AUTL) Stock Analysis: A Biotech Gem with 371.62% Potential Upside

Autolus Therapeutics plc (NASDAQ: AUTL), a pioneering player in the biotechnology sector, is capturing investor attention with a staggering potential upside of 371.62%, according to the..

Oruka Therapeutics, Inc. (ORKA): Investor Outlook with 85.81% Potential Upside and Exclusive Buy Ratings

Oruka Therapeutics, Inc. (NASDAQ: ORKA) is catching the eye of investors with its impressive potential upside of 85.81%, according to analyst ratings. This clinical-stage biopharmaceutical company,..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Unlocking a 36% Upside Potential in the Healthcare Sector

In the dynamic landscape of the healthcare sector, Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is capturing investor attention with its promising portfolio targeting rare diseases. With a..

Celcuity Inc. (CELC) Stock Analysis: A Biotech Powerhouse with 112% Upside Potential

Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, has captured the attention of investors with its promising pipeline of targeted therapies for..

Standard BioTools Inc. (LAB) Stock Analysis: Exploring an 85% Upside Potential

Standard BioTools Inc. (NASDAQ: LAB) is attracting investor attention with a compelling 85.36% potential upside, according to analyst target price projections. Operating within the healthcare sector,..

KalVista Pharmaceuticals (KALV): An Insight into Its Future Post-Privatization

KalVista Pharmaceuticals, Inc. (KALV), a notable player in the biotechnology industry with a market capitalization of $1.44 billion, has recently undergone a significant transition. As of..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating a Challenging Landscape with a 44% Potential Downside

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) stands at the forefront of biotechnology innovation, yet faces significant challenges that investors must carefully navigate. With a market capitalization..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a Potential 125% Upside in the Biotech Arena

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology firm, is making waves in the healthcare sector with its innovative approach to developing precision medicines targeting fibroblast..

RxSight, Inc. (RXST) Stock Analysis: Evaluating the 59% Upside Potential Amidst Volatile Performance

RxSight, Inc. (NASDAQ: RXST), a commercial-stage leader in the healthcare sector focused on medical devices, has garnered investor interest due to its unique product offering. Specializing..

Abivax SA (ABVX) Stock Analysis: A Biotech with a 72% Upside Potential

Abivax SA (ABVX), a Paris-based biotechnology firm, is capturing the attention of investors with its promising pipeline and significant upside potential. Operating within the healthcare sector,..

Prothena Corporation plc (PRTA): Investor Outlook on a Biotech Stock with 150% Potential Upside

Prothena Corporation plc (NASDAQ: PRTA), a biopharmaceutical company based in Dublin, Ireland, is making waves in the healthcare sector with its focus on novel therapies for..

CeriBell, Inc. (CBLL) Stock Analysis: Exploring a Promising 18.59% Potential Upside in the Healthcare Sector

CeriBell, Inc. (NASDAQ: CBLL), a cutting-edge player in the medical devices industry, is capturing the attention of investors with its promising potential upside of 18.59%. Specializing..

Stoke Therapeutics, Inc. (STOK) Stock Analysis: Unveiling a Promising 78.63% Potential Upside in Biotechnology

Stoke Therapeutics, Inc. (NASDAQ: STOK) has rapidly emerged as a formidable player in the biotechnology sector, attracting substantial investor interest due to its innovative approach to..

Kamada Ltd. (KMDA) Stock Analysis: Unlocking a 64.63% Potential Upside in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA), an Israeli-based player in the healthcare sector, stands out as an attractive proposition for investors eyeing the drug manufacturing industry, particularly in..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds